Cardiology
Reliant submits data supporting use of Omacor with statin to lower high triglycerides
Published in Medical Letter on the CDC and FDA, January 28th, 2007
As part of this filing, Reliant submitted new data from the recently completed Combination of Omacor and Simvastatin (COMBOS) trial that evaluated the efficacy and safety of Omacor as an adjunct to diet and simvastatin therapy for the treatment of high triglycerides. COMBOS is a randomized, double-blind, placebo-controlled, parallel-group study including 254 patients.
Omacor is the first and only...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Gastroenterology
Reports on gastroenterology findings from College of Medicine provide new insights - Women's Health
Recent findings from Medical School highlight research in women's health - Women's Health
Recent findings in women's health described by investigators from Howard University, Center for Minority Health Services Research - Allergy & Immunology
ISTA submits IND for eye drop formulation of bepotastine for allergic conjunctivitis - Alzheimer Disease
U.S. FDA approves IND from Siemens for clinical study of Alzheimer-specific imaging agent - Attention Deficit Hyperactivity Disorder
New River Pharmaceuticals, Shire receive approvable letter for Vyvanse - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
